Medtronic
the FDA approved Medtronic's Evolut FX+ TAVR for an expanded Redo-TAVR indication in August 2025, and Medtronic earned the CE Mark for redo-TAVI procedures, extending valve-in-valve therapy for high-risk patients.
- Country
- Ireland
- Ticker
- NYSE:MDT
Cardiovascular implants
FDA approved
CE Mark
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biomedical engineering & implants | regenerative-personalized | Medium | → |
| Implantable biosensors for chronic disease | diagnostics-medtech | Medium | → |
| Ingestible biosensors / smart pills | diagnostics-medtech | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.